> top > docs > PMC:7102591 > spans > 15969-17809 > annotations

PMC:7102591 / 15969-17809 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
493 5-13 Disease denotes tsDMARDs
512 1281-1286 Gene denotes JAK-1 Gene:3716
513 121-129 Species denotes patients Tax:9606
514 426-433 Species denotes patient Tax:9606
515 535-543 Species denotes patients Tax:9606
516 702-709 Species denotes patient Tax:9606
517 826-834 Species denotes patients Tax:9606
518 204-215 Chemical denotes tofacitinib MESH:C479163
519 220-231 Chemical denotes baricitinib MESH:C000596027
520 335-346 Chemical denotes tofacitinib MESH:C479163
521 649-660 Chemical denotes baricitinib MESH:C000596027
522 845-856 Chemical denotes tofacitinib MESH:C479163
523 1050-1060 Chemical denotes prednisone MESH:D011241
524 1308-1320 Chemical denotes upadacitinib MESH:C000613732
525 1325-1335 Chemical denotes filgotinib MESH:C584571
526 46-70 Disease denotes opportunistic infections MESH:D009894
527 118-120 Disease denotes RA MESH:D001172
528 308-318 Disease denotes infections MESH:D007239
529 532-534 Disease denotes RA MESH:D001172
531 1785-1813 Disease denotes respiratory virus infections

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T68 1612-1616 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T198 60-70 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T199 118-120 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T201 289-295 Disease denotes Zoster http://purl.obolibrary.org/obo/MONDO_0005609
T202 308-318 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T203 532-534 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T205 975-984 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T206 1080-1089 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T207 1413-1423 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T208 1797-1813 Disease denotes virus infections http://purl.obolibrary.org/obo/MONDO_0005108

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T115 296-301 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T116 570-571 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T117 588-591 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T118 1038-1044 http://purl.obolibrary.org/obo/UBERON_0003100 denotes female
T119 1211-1212 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T120 1225-1227 http://purl.obolibrary.org/obo/CLO_0054055 denotes 71
T121 1445-1446 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T122 1612-1616 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T123 1656-1665 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T124 1674-1699 http://purl.obolibrary.org/obo/PR_000024990 denotes type I and II interferons
T125 1797-1802 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T121 104-114 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T122 118-120 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T123 204-215 Chemical denotes tofacitinib http://purl.obolibrary.org/obo/CHEBI_71200
T124 335-346 Chemical denotes tofacitinib http://purl.obolibrary.org/obo/CHEBI_71200
T125 532-534 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T126 845-856 Chemical denotes tofacitinib http://purl.obolibrary.org/obo/CHEBI_71200
T127 1050-1060 Chemical denotes prednisone http://purl.obolibrary.org/obo/CHEBI_8382
T128 1297-1307 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T129 1646-1655 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T130 1685-1687 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T131 1829-1839 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T23 1612-1634 http://purl.obolibrary.org/obo/GO_0002456 denotes cell-mediated immunity
T24 1612-1634 http://purl.obolibrary.org/obo/GO_0002449 denotes cell-mediated immunity
T25 1656-1665 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T85 0-13 Sentence denotes 4.4 tsDMARDs
T86 14-324 Sentence denotes The overall risk of serious and opportunistic infections observed with Janus Kinase (JAK) inhibitors in RA patients is roughly comparable with bDMARDs [64,65], although these early years of tofacitinib and baricitinib use have raised the issue of an increased risk of Herpes Zoster virus (HZV) infections [66].
T87 325-569 Sentence denotes Data from tofacitinib pooled population enrolled in RCTs showed an HZV incidence rate of 4.0 per 100 patient-years (with greater incidence in geographic area with high HZV endemicity), doubling the rates of RA patients not receiving JAKis [67].
T88 570-721 Sentence denotes A similar picture has also been observed in the overall development program of baricitinib, with an incidence rate of 3.2 cases per patient-years [68].
T89 722-1026 Sentence denotes The subsequent real-life experience from US claim databases revealed that the risk of HZV was higher in patients receiving tofacitinib compared to those treated with abatacept (aHR 2.01 (95% CI 1.40; 2.88) [69], and the risk of serious hospitalized HZV infection is 2-fold higher versus all bDMARDs [70].
T90 1027-1229 Sentence denotes Older age, female sex, prednisone >7.5 mg/day, prior infection, and greater number of hospitalizations were associated with increased HZV risk, whereas vaccination was associated with a lower risk [71].
T91 1230-1477 Sentence denotes More recent reports from RCTs conducted with novel JAK-1 selective inhibitors upadacitinib and filgotinib have basically confirmed the same trend, suggesting that the increase in HZV infections can be considered as a class effect of JAKis [72,73].
T92 1478-1736 Sentence denotes Although the exact mechanism by which HZV reactivation occurs in the context of JAK inhibition is unclear, the downregulation of both cell-mediated immunity and innate antiviral signaling through type I and II interferons (IFN) is likely to be involved [74].
T93 1737-1840 Sentence denotes Currently, no data are available on the risk of respiratory virus infections carried by JAK inhibitors.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T63 46-70 Phenotype denotes opportunistic infections http://purl.obolibrary.org/obo/HP_0031690
T64 118-120 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T65 532-534 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370

2_test

Id Subject Object Predicate Lexical cue
32205186-31733368-4826903 169-171 31733368 denotes 65
32205186-30219772-4826904 717-719 30219772 denotes 68
32205186-27113415-4826905 929-931 27113415 denotes 69
32205186-30183607-4826906 1225-1227 30183607 denotes 71
32205186-31692920-4826907 1470-1472 31692920 denotes 72
32205186-31520803-4826908 1473-1475 31520803 denotes 73
32205186-28250461-4826909 1732-1734 28250461 denotes 74